- Home
- AIRE vs NRXP Comparison
AIRE vs NRXP Comparison
Compare AIRE & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIRE | NRXP |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 62.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | AIRE | NRXP |
|---|---|---|
| Price | $0.29 | $1.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $2.00 | ★ $31.50 |
| AVG Volume (30 Days) | ★ 1.3M | 509.9K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $948,420.00 | N/A |
| Revenue This Year | $470.21 | N/A |
| Revenue Next Year | $143.58 | $847.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $1.58 |
| 52 Week High | $1.55 | $3.84 |
Technical Indicators
Market Signals| Indicator | AIRE | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 33.00 | 39.61 |
| Support Level | $0.14 | $1.65 |
| Resistance Level | $0.35 | $1.99 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 4.05 | 12.90 |
Price Performance
Historical ComparisonAbout AIRE reAlpha Tech Corp.
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.